Skip to content

Study · Non-randomized trial · n = 10 · 1990

4 results

Perinatal growth hormone (GH) physiology: effect of GH-releasing factor on maternal and fetal secretion of pituitary and placental GH.

de Zegher F, Vanderschueren-Lodeweyckx M, Spitz B, Faijerson Y, Blomberg F, Beckers A, Hennen G, Frankenne F

The Journal of clinical endocrinology and metabolism1 Aug 1990Cited by 37 (Europe PMC)

PMID2143200 (opens in a new tab)DOI10.1210/jcem-71-2-520 (opens in a new tab)PepBankPUB-02143200
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In pregnant women at term, maternal sermorelin did not change cord serum hGH concentrations of infants versus saline controls.

    In plain wordsIn pregnant women at term, sermorelin given to the mother did not change the baby's cord blood growth hormone compared with saline.

    Peptide
    Sermorelin
    Outcome
    No significant changeCord serum hGH concentration
    Study

    n = 10

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Cord serum hGH concentrations were similar in infants of GRF-(1-29)-NH2-injected mothers and control infants.
    1 context sentence
    Summary · context
    To study regulation of the secretion of human pituitary GH (hGH) and placental GH (hPGH) in the pregnant woman and human fetus, the GH-releasing factor Sermorelin [GRF-(1-29)-NH2] was administered to pregnant women at term (n = 5), just before elective cesarean section; saline was administered in co…
  2. 02HumanNon-randomized trialEfficacy outcome

    In pregnant women at term, sermorelin produced a small rise in maternal hGH that was not significant (P = 0.08) versus saline.

    In plain wordsIn pregnant women at term, sermorelin caused a small rise in the mother's growth hormone, not statistically significant compared with saline.

    Peptide
    Sermorelin
    Outcome
    No significant changeMaternal serum hGH concentration
    Study

    n = 10

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Measurements

    P value
    0.08
    maternal hGH

    Source sentences

    Summary
    GRF-(1-29)-NH2 elicited a consistent but small rise in maternal hGH serum concentrations (P = 0.08)
    1 context sentence
    Summary · context
    To study regulation of the secretion of human pituitary GH (hGH) and placental GH (hPGH) in the pregnant woman and human fetus, the GH-releasing factor Sermorelin [GRF-(1-29)-NH2] was administered to pregnant women at term (n = 5), just before elective cesarean section; saline was administered in co…
  3. 03HumanNon-randomized trialEfficacy outcome

    In pregnant women at term, sermorelin did not alter maternal placental GH (hPGH) concentrations.

    In plain wordsIn pregnant women at term, sermorelin did not change placental growth hormone levels in the mother's blood.

    Peptide
    Sermorelin
    Outcome
    No significant changeMaternal serum hPGH concentration
    Study

    n = 10

    Comparator
    Saline
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    whereas hPGH concentrations remained unaltered.
    1 context sentence
    Summary · context
    To study regulation of the secretion of human pituitary GH (hGH) and placental GH (hPGH) in the pregnant woman and human fetus, the GH-releasing factor Sermorelin [GRF-(1-29)-NH2] was administered to pregnant women at term (n = 5), just before elective cesarean section; saline was administered in co…
  4. 04HumanNon-randomized trialPharmacokinetics

    In pregnant women at term, sermorelin was undetectable in cord serum but readily detectable in maternal serum.

    In plain wordsIn pregnant women at term, sermorelin was found in the mother's blood but not in the baby's cord blood.

    Peptide
    Sermorelin
    Outcome
    Not applicableSermorelin concentration in cord and maternal serum
    Study

    n = 10

    Comparator
    Saline
    Outcome group
    Pharmacokinetics · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Finally, GRF-(1-29)-NH2 concentrations were undetectable in cord serum, but readily detectable in concomitantly obtained maternal serum.
    1 context sentence
    Summary · context
    To study regulation of the secretion of human pituitary GH (hGH) and placental GH (hPGH) in the pregnant woman and human fetus, the GH-releasing factor Sermorelin [GRF-(1-29)-NH2] was administered to pregnant women at term (n = 5), just before elective cesarean section; saline was administered in co…

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 10:21 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.